Answers are grounded in this paper and cite their sources.
This review demonstrates advancements in drug delivery systems to improve solubility and therapeutic efficacy for Class II and IV drugs, suggesting new formulation strategies and nanotechnology's role
The limited oral bioavailability of drugs categorized under the Biopharmaceutics Classification System (BCS) Class II and IV poses a significant challenge due to their poor aqueous solubility and, in the case of Class IV, low permeability as well. This review critically evaluates both conventional and advanced formulation strategies aimed at overcoming these barriers to improve drug absorption and therapeutic efficacy. Traditional techniques, such as salt formation, solid dispersions, and micronization, have offered partial success but often face limitations in scalability and stability. In contrast, modern approaches—particularly those based on nanotechnology—have revolutionized the formulation landscape. Systems, such as nanocrystals, liposomes, solid lipid nanoparticles, and polymeric carriers, not only enhance solubility but also enable targeted and controlled drug delivery. Emerging technologies, including 3D printing, artificial intelligence (AI)-driven design, and nanorobotics, further promise personalized, efficient, and adaptive drug delivery systems. This review highlights the mechanisms, advantages, and limitations of each approach, supported by commercial case studies such as Doxil®, Kaletra®, Neoral®, and Entresto®, underscoring their translational relevance. Collectively, these advancements provide a strategic framework for transforming poorly bioavailable drugs into clinically effective therapies, while also addressing regulatory, economic, and manufacturing considerations.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: